DayOne gains importance
DayOne, a BaselArea.swiss initiative, is creating a world-leading healthcare innovation hub based on the strengths of the Basel region. A further important partner has joined to help achieve this goal.
The Department of Biosystems (D-BSSE) in Basel, which is part of the Federal Institute of Technology in Zurich (ETH), has become the latest partner of DayOne, according to a statement. With the partnership, the department will help promote digital healthcare applications and create a world-leading center for precision medicine.
Its goals are in line with those of BaselArea.swiss, which operates the DayOne initiative. BaselArea.swiss has access to sector and technology experts, doctors and scientists, and is planning to exploit the know-how of around 2,000 healthcare innovators currently based in the Basel region.
The initiative DayOne has six core activities – among them supporting the existing network, launching pioneering projects and providing collaborative workspaces. Another aspect is helping companies from abroad to settle in the Basel region, which BaselArea.swiss specializes in. Furthermore the initiative announced news concerning the other two core activities.
On September 9, the next DayOne Conference will be held at the University of Applied Sciences and Arts Northwestern Switzerland (FHNW) in Muttenz in the canton of Basel-Landschaft. Entitled “Shaping the Future of Health”, the conference is expected to attract around 400 innovators, patients and experts. It will look at topics including digitalization and ethics, and will showcase innovations from the DayOne Accelerator and others.
The accelerator is the initiative’s sixth core activity. BaselArea.swiss and the partner organizations received more than 150 applications for the accelerator, twice as many as last year. The 16 companies considered for the first round of the accelerator can present their projects at the DayOne Conference. Four companies will then be selected for funding under the accelerator from January 2020.
Share this article
You might also be interested in
The Basel-based biotechnology firm VectivBio has received a capital injection of 110 million US dollars from both new and existing...Read More
The Allschwil-based company Polyphor has received a second funding award from the global consortium CARB-X to combat antimicrobial resistance. Polyphor...Read More
The COVID-19 pandemic has hit economies worldwide – and we have not yet overcome it. However, Switzerland is among the...Read More
The Basel-based biotechnology firm Monte Rosa Therapeutics has raised a total of 96 million US dollars after closing a successful...Read More
The Basel-based pharmaceutical supplier Lonza is supporting the US firm Humanigen in the development of a potential coronavirus therapeutic. Lonza...Read More